INS and type 2 diabetes mellitus: OW semaglutide is indicated in subjects with uncontrolled type 2 diabetes as a monotherapy when the use of metformin is contraindicated, or as an add-on therapy with other glucose-lowering drugs, including insulin (18, 19); furthermore, based on the most recent guidelines, it can be considered for use as a first-line therapy in T2D patients with previous CV event (2, 20).